(AAPL) Apple’s iPhone is not being delayed according to AT&T (Cingular).
(ALTH) Allos Therapeutics’s PDX Granted Orphan Medicinal Product Designation by the European Commission.
(AME) Ametek $0.48 EPS vs $0.46e.
(ARB) Arbitron $0.52 EPS vs $0.50e.
(BAC) Bank of America $1.17 EPS vs $1.15e.
(BAX) Baxter $0.61 EPS vs $0.55e.
(BBT) BB&T $0.81 EPS vs $0.77e.
(BOT) CBOT $1.29 EPS vs $1.16e.
(BWA) Borg Warner noted positively by Cramer for green investing.
(DGX) Quest Diagnostics $0.79 EPS vs $0.69e.
(DHI) $0.16 EPS vs $0.27e; $0.32 EPS was raw number.
(DHR) Danaher $0.78 EPS vs $0.77e.
(EBAY) eBay traded up 5% after beating earnings.
(EBS) Emergent Biosolutions announces that HHS and DoD issued notices of intent to procure up to a combined 22.75 mln doses of BioThrax.
(FCBP) First Community Bancorp $0.98 EPS vs $0.86e.
(GERN) Geron says Studies Confirm Proof-of-Principle for it’s Human Embryonic Stem Cell Derived Hepatocytes.
(GILD) Gilead traded up to new year highs in after-hours trading after beating earnings expectations.
(HSY) Hershey Foods $0.51 EPS vs $0.51e.
(HYGS) Hydrogenics signed multiple HyPM Fuel Cell orders.
(KVHI) KVH Industries $0.00 EPS vs $0.02e.
(LOGI) Logitech $0.29 EPS vs $0.30e.
(MER) Merrill Lynch $2.26 EPS vs $1.97e.
(MO) Altria $1.03 EPS vs $1.05e.
(MSFT) Microsoft in license pact with Samsung.
(MRK) Merck $0.84 EPS vs $0.84e; guides next Q $0.67 to $0.71 EPS vs $0.69e.
(NRMX) Neurochem says database for North American Phase III clinical trial for tramiprosate for treatment of Alzheimer’s disease has been locked up.
(ORB) Orbital Sciences $0.19 EPS vs $0.19e; guidance looks in-line to slightly above prior range.
(PTMK) Pathmark Stores $0.03 EPS vs -$0.03e.
(SPNC) Spectranetics $0.00 EPS vs -$0.01e.
(STJ) St. Jude Medical is selling $1B in convertible notes.
(TER) Teradyne trading up over 2% after earnings.
(UNH) UnitedHealth $0.74 EPS vs $0.71e.
(VICL) Vical is expanding testing of its Vaxfectin adjuvant to U.S. Navy malaria vaccine program.
(WYE) Wyeth $0.94 EPS vs $0.88e.
(YHOO) Yahoo!’s CEO Terry Semel noted as #1 CEO who needs to go by Cramer.
Jon C. Ogg
April 19, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.